152 related articles for article (PubMed ID: 10432950)
41. [Skin necrosis induced by heparin: apropos of 2 cases].
Andolfatto S; Latger-Cannard V; Maistre ED; Briquel ME; André E; Montange F; Reichert S; Lecompte T
Ann Biol Clin (Paris); 2001; 59(5):651-4. PubMed ID: 11602401
[No Abstract] [Full Text] [Related]
42. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
[TBL] [Abstract][Full Text] [Related]
43. Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II.
Janssens U; Breithardt OA; Greinacher A
Pacing Clin Electrophysiol; 1999 Apr; 22(4 Pt 1):678-81. PubMed ID: 10234725
[TBL] [Abstract][Full Text] [Related]
44. HIT/HITT and alternative anticoagulation: current concepts.
Lakshmanan S; Saha B; Rittoo D
Br J Anaesth; 2003 Sep; 91(3):445; author reply 445-6. PubMed ID: 12966934
[No Abstract] [Full Text] [Related]
45. Ardeparin and danaparoid for prevention of deep vein thrombosis.
Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
[No Abstract] [Full Text] [Related]
46. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
[TBL] [Abstract][Full Text] [Related]
47. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
[TBL] [Abstract][Full Text] [Related]
48. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects.
Castelli R; Cassinerio E; Cappellini MD; Porro F; Graziadei G; Fabris F
Cardiovasc Hematol Disord Drug Targets; 2007 Sep; 7(3):153-62. PubMed ID: 17896955
[TBL] [Abstract][Full Text] [Related]
49. Treatment of heparin-induced thrombocytopenia.
Dager WE; White RH
Ann Pharmacother; 2002 Mar; 36(3):489-503. PubMed ID: 11895064
[TBL] [Abstract][Full Text] [Related]
50. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
Hill GR; Hickton C; Henderson S; Patton WN
Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
[TBL] [Abstract][Full Text] [Related]
51. [Heparin-induced type II thrombocytopenia within the scope of high dose chemotherapy with subsequent stem cell rescue].
Sauer M; Gruhn B; Fuchs D; Altermann W; Zintl F
Klin Padiatr; 1998; 210(3):102-5. PubMed ID: 9629542
[TBL] [Abstract][Full Text] [Related]
52. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
Greinacher A
N Engl J Med; 2015 Jul; 373(3):252-61. PubMed ID: 26176382
[No Abstract] [Full Text] [Related]
53. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin.
Keng TB; Chong BH
Br J Haematol; 2001 Aug; 114(2):394-6. PubMed ID: 11529862
[TBL] [Abstract][Full Text] [Related]
54. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
[TBL] [Abstract][Full Text] [Related]
55. A case of heparin-induced thrombocytopenia with repeated episodes of acute lower extremity arterial thromboembolism during a short time.
Masumoto H; Shimamoto M; Yamazaki F; Nakai M; Fujita S; Itonaga T; Nomura R
Ann Thorac Cardiovasc Surg; 2007 Oct; 13(5):365-7. PubMed ID: 17954999
[TBL] [Abstract][Full Text] [Related]
56. [Delayed hypersensitivity to heparins and heparinoids].
Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
[TBL] [Abstract][Full Text] [Related]
57. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
[No Abstract] [Full Text] [Related]
58. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
[TBL] [Abstract][Full Text] [Related]
59. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG.
Harenberg J; Huhle G; Wang L; Hoffmann U; Bayerl C; Kerowgan M
Allergy; 1999 May; 54(5):473-7. PubMed ID: 10380778
[TBL] [Abstract][Full Text] [Related]
60. New treatment options for heparin-induced thrombocytopenia.
Ortel TL; Chong BH
Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
